Dapagliflozin for Lupus Nephritis
Dapagliflozin in Active Lupus Nephritis
Recruiting
Phase 4
Interventional Study
Lupus Nephritis (LN)
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 70
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 33 (estimated)
- Sponsor
- Brigham and Women's Hospital · Other
Who this trial is looking for
This trial is looking for people aged 18-70 with active lupus nephritis. Participants will receive dapagliflozin or a placebo alongside their usual treatments.
Are You a Good Fit for This Trial?
You may be able to join if
- I am between 18 and 70 years old.
- I have been diagnosed with lupus and have proven kidney involvement.
- I have active lupus nephritis within the past six months.
- I am receiving standard treatment for active lupus nephritis.
- I have used glucocorticoids for my condition in the past 6 months.
- I have protein in my urine above a certain level.
- I can give my informed consent.
You may not be able to join if
- I have severely reduced kidney function.
- I have had a sudden increase in creatinine in the last 90 days.
- I have type 1 diabetes.
- I am underweight with a BMI under 18.5.
- I currently have an active cancer or infection.
- I am pregnant or planning to become pregnant without contraception.
- I am taking too much prednisone right now.
- I have used certain diabetes medications before.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Lupus nephritis is a chronic and life-threatening autoimmune cause of kidney disease that predominately impacts young people and can lead to kidney failure. Sodium-glucose co-transporter-2 inhibitors, including dapagliflozin, are known to improve outcomes for people with other causes of chronic kidney disease. This pilot and feasibility randomized clinical trial will test the use of dapagliflozin …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* • Age 18-70 years, fulfilling 2012 SLICC or 2019 ACR/EULAR criteria for SLE, with biopsy-proven class III, IV and/or V LN
* Active (new or relapsing) LN within the prior six months, with at least one of the following:
* Kidney biopsy with activity index \>2 and/or
…
Contacts